LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026)
LeonaBio's (LONA) quarterly Total Non-Current Liabilities came in at $21.1 million in Q1 2026, down 66.54% on a QoQ basis from $63.0 million in Q4 2025.
LeonaBio (LONA) Total Non-Current Liabilities (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has 3 years of Total Non-Current Liabilities data on file, last reported at $21.1 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities changed N/A year-over-year to $21.1 million in Q1 2026; TTM through Mar 2026 was $21.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at $63.0 million, changed N/A from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $21.1 million, down from $63.0 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for LONA reached as high as $63.0 million in Q4 2025 and fell as low as $21.1 million in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 746.94 Mn |
| 10 | LeonaBio | 138.33 Mn | 70.65 Mn | - | 21.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 21.07 Mn |
| Dec 31, 2025 | 62.96 Mn |
| Dec 31, 2019 | 3.86 Mn |